Olmesartan comes through for Daiichi Sankyo
This article was originally published in Scrip
Executive Summary
Sales and profits at Daiichi Sankyo came in ahead of the company's own forecasts for the first half to September 30th, helped by strong US sales, non-operating gains from the valuation of Ranbaxy's foreign exchange derivatives and the one-off sale of investment securities.